All News

Fatigue, FM, fibromyalgia

Fibromyalgianess Influences Steroid Persistence

d Jack Cush, MD

"Fibromyalgianess" is highlighted as a risk factor for undue, extended glucocorticoid use in rheumatoid arthritis (RA) patients, according to Wallace and colleagues in Rheumatology.

Read Article
RheumNow Podcast square

RheumNow Podcast – Psoriatic Arthritis Without Psoriasis (7.30.2021)

d Jack Cush, MD

How much psoriasis do you need to have in order to have psoriatic arthritis? This plus a review of rheumatology and COVID news from the past week on RheumNow.com.

Read Article
shingles_0.jpg

Shingles Risk with JAK Inhibitors and Other Biologics

d Jack Cush, MD

Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.

Read Article
38420215_s.jpg

No Cancer Risk with TNF Inhibitors in Rheumatoid Arthritis

d Jack Cush, MD

The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs).

Read Article
RA, hands, MCP, deformity

Combo Methotrexate and Leflunomide Safety in RA

d Jack Cush, MD

Methotrexate and leflunomide (LEF) are the most widely prescribed DMARDs worldwide; yet biologic DMARDs are the newest and best selling agents for rheumatoid arthritis worldwide.

Read Article
RheumNow Podcast – Psoriatic Arthritis Without Psoriasis Download wherever you get your podcasts! https://t.co/Ra5f7507XT https://t.co/5WqPCgGVpr

Links:

Dr. John Cush RheumNow ( View Tweet)
Did you see this tweet from May? Worth re-sharing. Rituximab Tops Mycophenolate Mofetil for Pemphigus Vulgaris. One year study of 135 moderate-to-severe pemphigus patients saw complete remission in 40% of RTX vs 10% of MMF patients. https://t.co/yAauFRjHCe https://t.co/bibHXaHtWf

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w

Links:

Dr. John Cush RheumNow ( View Tweet)

New podcast available for download! We focus on the articles shared this week on https://t.co/V10S4oVFsv . https://t.co/Ra5f7507XT https://t.co/Pz0RFxLIOx

Links:

Dr. John Cush RheumNow ( View Tweet)
Swiss SCQM registry compared 3217 RA & 819 PsA pts; PsA had more obese (36.5% overweight, 23.8% obese) than RA (4.4% underweight, 31.8% overweight, 17.0% obese). Obese PsA had higher CRP, Dz activity, worse QOL, pain & skin https://t.co/UzbKlT3tSz

Links:

Dr. John Cush RheumNow ( View Tweet)

Literature review examined safety of IL-17 inhibitors in 106 controlled RCTs, 40,053 pts. Inflammatory bowel disease was reported in 0.4% of IL-17i Rx patients. (same in 61 uncontrolled RCTs -0.36%). Other AE: diarrhea (2.5%), N/V(0.7%) https://t.co/2wSZQqB1Zs

Links:

Dr. John Cush RheumNow ( View Tweet)

JAMA article on using new features in Updated PubMed: 1) Focus the Clinical Question 2) Use PubMed Clinical Query Filters 3) Refine the Search Terms https://t.co/ExK8p2hVnX

Links:

Dr. John Cush RheumNow ( View Tweet)

Comparison of 1040 elderly-onset RA (EORA) and 710 non-EORA patients showed similar disease activity, DMARD choices, drug response rates and reasons for Rx discontinuation - There's no reason EORA shouldn't be treated as aggressive as all RA! https://t.co/P2gpPlJVZE

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Drugs capable of inducing drug-associated ANCA vasculitis - mirabegron (Myrbetriq), sofosbuvir (Sovaldi, antiviral), nintedanib (Ofev), hydralazine, propylthiouracil, thiamazole, minocycline, carbimazole, allopurinol, influenza vax.... https://t.co/KhK2w0IGAx

Links:

Dr. John Cush RheumNow ( View Tweet)

Health personnel (HCP) @ long-term care facilities (LTCFs) are at high risk for COVID-19. March 2021, 57% of LTCF HCPs were vaccinated. COVID-19 vax was highest in MDs (75.1%); lowest nurses (56.7%) & aides (45.6%). https://t.co/VjHutcrh26

Links:

Dr. John Cush RheumNow ( View Tweet)

The FDA has authorized baricitinib ALONE as treatment for COVID-19 hospitalized adults and pediatric patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) https://t.co/WMc78GmOLU

Links:

Dr. John Cush RheumNow ( View Tweet)

What predicts ILD progression in Systemic Sclerosis? Study of 138 SSc pts; 72% had ILD, 35% FVC decline (F/U 2.9y). Only Scl-70 A positivity predicted FVC decline at 5yrs. HRCT Esophageal dilation had nonsignificant DLCO decline, but not FVC https://t.co/fE0JCsZ44O

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: EULAR guidelines rec starting prednisone dose in #PMR to be between 12.5-25mg/d. A cross sectional study of 138 pts (63M, 75F, age 73.4 yes) saw the mean starting dose to be 19.2±7.7 mg.  https://t.co/Yf3yqRRMCK

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI While myeloperoxidase (MPO) Abs are seen in idiopathic pulmonary fibrosis (IPF), only 7–23% develop vasculitis. Study of 58 pts w/ IPF & MPO Abs - UIP most frequent ILD pattern, 13 had rheumatic dz; MPO Abs did not change survival of UIP/IPF pts https://t.co/RXXIPUBMBT https://t.co/sJpbzIbBJt

Links:

Dr. John Cush RheumNow ( View Tweet)
Big news! You can download/listen to the RheumNow podcast in more places than ever! Find us on Apple and Google podcasts, the PodBean app, Spotify, Pandora, TuneIn+Alexa, iHeart Radio, PlayerFM, Listen Notes, Stitcher, Overcast, Pocket Cast, Castro, Castbox, and Soundcloud! https://t.co/1WSUh06jjN
Dr. John Cush RheumNow ( View Tweet)
×